Magprol CR 400 Tablet contains Magnesium Valproate 400 mg, an anticonvulsant and mood-stabilizing agent primarily used in the management of epilepsy and bipolar disorder. Magnesium Valproate acts by increasing gamma-aminobutyric acid (GABA) levels in the brain, thereby exerting an inhibitory effect on neuronal excitability and preventing seizure activity. The controlled-release formulation ensures a sustained therapeutic effect, improving patient compliance by reducing dosing frequency and minimizing fluctuations in plasma drug concentration. Magprol CR 400 is indicated for the treatment of various seizure types, including generalized tonic-clonic, absence, and complex partial seizures, as well as for the prophylaxis of manic episodes in bipolar affective disorder. The medication should be administered under medical supervision, with dosage individualized based on clinical response and tolerability. Common adverse effects may include gastrointestinal disturbances, dizziness, weight gain, and tremor, while rare but serious side effects such as hepatotoxicity and pancreatitis require prompt medical attention. Regular monitoring of liver function tests, blood counts, and serum valproate levels is recommended during therapy. Magprol CR 400 should be used cautiously in patients with hepatic impairment, mitochondrial disorders, or hypersensitivity to valproate compounds. It is contraindicated during pregnancy due to teratogenic risk.